Telix Pharmaceuticals Limited

TLX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$12.59+0.64%

2026-09-18

Financials

Valuation Metrics

Telix Pharmaceuticals Limited's Market Cap is $4.27B. Ranked #1480 of 3,121 in US market (top 47%), #513 of 1,463 on NASDAQ (top 35%), #87 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$4.27B	US#1,480/3,121 Sec#87/266
Revenue	$777M	US#2,033/3,121 Sec#62/266
Net Income	$-7M	US—/3,121 Sec—/266
Total Assets	$1.19B	US#2,397/3,121 Sec#89/266
Net Assets	$417M	US#2,354/3,121 Sec#130/266
Value
P/B	10.23x	US#2,622/3,121 Sec#196/266
P/S	5.49x	US#2,358/3,121 Sec#78/266
EV/EBITDA	89.18x	US#2,430/3,121 Sec#78/266
FCF Yield	-1.25%	US—/3,121 Sec—/266
Profitability
ROE	-1.65%	US#2,182/3,121 Sec#67/266
ROA	-0.58%	US#2,287/3,121 Sec#73/266
Op. Margin	2.21%	US#2,243/3,121 Sec#76/266
Revenue Growth	53.91%	US#207/3,121 Sec#48/266
Earnings Growth	-121.41%	US#1,914/3,121 Sec#57/266
Financial Health
Debt Ratio	184.59%	US#1,715/3,121 Sec#197/266
Total Debt	$469M	US#1,903/3,121 Sec#64/266
FCF	$-53M	US#2,531/3,121 Sec#114/266
Cash	$142M	US#1,985/3,121 Sec#139/266
Current Ratio	1.43x	US#1,755/3,121 Sec#243/266
Net Debt/EBITDA	6.34x	US#2,184/3,121 Sec#79/266
Performance
1Y Return	37.45%	US#838/3,121 Sec#136/266
1M Return	3.88%	US#467/3,121 Sec#49/266
From 52W High	-3.97%	US#277/3,121 Sec#22/266
1Y MDD	-41.78%	US#2,095/3,121 Sec#146/266
Trading
Volume	184,723 shares	US#2,179/3,121 Sec#223/266
Trading Value	$2M	US#2,648/3,121 Sec#221/266
Per Share
EPS	$-0.02	US—/3,121 Sec—/266
BPS	$1.23	US#2,665/3,121 Sec#196/266